Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.49 |
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722006 | 0.85 | MAPK1 (0.57) | FPR2DHODHMAPK1 | |
| SCHEMBL4718395 | 0.81 | SMPD1 (0.52) | PDE4DPDE4BPDE4APDE4CDHODH | |
| SCHEMBL4718383 | 0.78 | SCN9A (0.47) | DHODHMAPK1 | |
| SCHEMBL4720507 | 0.78 | MAPT (0.46) | DHODHMAPK1 | |
| SCHEMBL4721287 | 0.77 | KDM4E (0.46) | PDE4BMAPK1 | |
| SCHEMBL29024878 | 0.76 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL71158 | 0.75 | TRPC6 (0.48) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4278555 | 0.75 | PDE4B (0.63) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1965584 | 0.75 | PDE4A (0.65) | PDE4DFPR2PDE4BPDE4APDE4C | |
| SCHEMBL28333942 | 0.74 | PDE4B (0.47) | PDE4DFPR2PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1396487-B1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2004-09-30 | — | — | US | disclosed |
| EP-1396487-A1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | PDE5A, PDE4A, PDE3B | PDE4D 7/4885FPR2 3722/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.